Skip to main content
  • Medicaid Provider Alert: Provider revalidation has begun and those not completing the process risk disenrollment.  Check your account now to learn when your revalidation is due. More information here.
Elizabeth M. Whitehorn, Director

Provider Notice issued 06/02/2023

 

Date: June 2, 2023
​To: All Medical Assistance Program Providers
​Re: Hepatitis C Drug Prior Authorization Removal Effective July 1, 2023

This notice confirms that the Department of Healthcare and Family Services (HFS) will remove prior authorization requirements for preferred Hepatitis C drugs effective July 1, 2023. This policy applies to the HFS fee-for-service program and the managed care organizations (MCOs).

Prescribing practitioners are required to get at least one hour of continuing medical education (CME) that is focused on diagnosis, appropriate management, and recommended follow-up of patients with Hepatitis C and approved or accredited by an organization such as: the Centers for Disease Control (CDC); the Accreditation Council for Continuing Medical Education (ACCME) or its state designee; a specialty society accredited to provide CME; an accredited medical school; or a university affiliated hospital.

HFS will be implementing a process for attestation of this required training through IMPACT via upload options. Prescribing practitioners must provide proof of training to HFS once the attestation process is established. HFS will supply additional information regarding the specifics of the attestation process when it becomes available. 

Questions regarding this notice may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565.  

 

  

Kelly Cunningham, Administrator

Division of Medical Programs